GSTM5 as a Potential Biomarker for Treatment Resistance in Prostate Cancer Porras-Quesada, Patricia Chica-Redecillas, Lucía Álvarez-González, Beatriz Gutiérrez-Tejero, Francisco Arrabal-Martín, Miguel Ríos-Pelegrina, Rosa Martínez-González, Luis Javier Álvarez-Cubero, Maria Jesus Vázquez-Alonso, Fernando castration-resistant prostate cancer GSTM5 biomarker Background/Objectives: Androgen deprivation therapy (ADT) is widely used to manage prostate cancer (PC), but the emergence of treatment resistance remains a major clinical challenge. Although the GST family has been implicated in drug resistance, the specific role of GSTM5 remains poorly understood. This study investigates whether GSTM5, alone or in combination with clinical variables, can improve patient stratification based on the risk of early treatment resistance. Methods: In silico analyses were performed to examine GSTM5’s role in protein interactions, molecular pathways, and gene expression. The rs3768490 polymorphism was genotyped in 354 patients with PC, classified by ADT response. Descriptive analysis and logistic regression models were applied to evaluate associations between genotype, clinical variables, and ADT response. GSTM5 expression related to the rs3768490 genotype and ADT response was also analyzed in 129 prostate tissue samples. Results: The T/T genotype of rs3768490 was significantly associated with a lower likelihood of early ADT resistance in both individual (p = 0.0359, Odd Ratios (OR) = 0.18) and recessive models (p = 0.0491, OR = 0.21). High-risk classification according to D’Amico was strongly associated with early progression (p < 0.0004; OR > 5.4). Combining genotype and clinical risk improved predictive performance, highlighting their complementary value in stratifying patients by treatment response. Additionally, GSTM5 expression was slightly higher in T/T carriers, suggesting a potential protective role against ADT resistance. Conclusions: The T/T genotype of rs3768490 may protect against ADT resistance by modulating GSTM5 expression in PC. These preliminary findings highlight the potential of integrating genetic biomarkers into clinical models for personalized treatment strategies, although further studies are needed to validate these observations. 2025-09-19T08:11:32Z 2025-09-19T08:11:32Z 2025-08-01 journal article Porras-Quesada, P.; ChicaRedecillas, L.; Álvarez- González, B.; Gutiérrez-Tejero, F.; Arrabal-Martín, M.; Rios-Pelegrina, R.; MartínezGonzález, L.J.; Álvarez-Cubero, M.J.; Vázquez-Alonso, F. GSTM5 as a Potential Biomarker for Treatment Resistance in Prostate Cancer. Biomedicines 2025, 13, 1872. https://doi.org/10.3390/ biomedicines13081872 https://hdl.handle.net/10481/106460 10.3390/ biomedicines13081872 eng http://creativecommons.org/licenses/by/4.0/ open access Atribución 4.0 Internacional MDPI